Filter News
Area of Research
- (-) Neutron Science (3)
- (-) Nuclear Science and Technology (2)
- Biology and Environment (4)
- Clean Energy (8)
- Computational Biology (1)
- Electricity and Smart Grid (1)
- Functional Materials for Energy (1)
- Fusion and Fission (7)
- Isotopes (2)
- Materials (23)
- Materials for Computing (3)
- National Security (5)
- Sensors and Controls (1)
- Supercomputing (9)
News Topics
- (-) Biomedical (2)
- (-) Isotopes (2)
- (-) Materials Science (3)
- (-) Security (1)
- 3-D Printing/Advanced Manufacturing (1)
- Advanced Reactors (1)
- Artificial Intelligence (2)
- Bioenergy (1)
- Biology (2)
- Composites (1)
- Computer Science (2)
- Cybersecurity (1)
- Decarbonization (1)
- Energy Storage (2)
- Environment (1)
- Frontier (1)
- Materials (3)
- Molten Salt (3)
- Nanotechnology (1)
- National Security (1)
- Neutron Science (14)
- Nuclear Energy (4)
- Physics (2)
- Quantum Science (1)
- Space Exploration (1)
- Summit (1)
- Transportation (1)
Media Contacts
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
A team of scientists, led by University of Guelph professor John Dutcher, are using neutrons at ORNL’s Spallation Neutron Source to unlock the secrets of natural nanoparticles that could be used to improve medicines.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.